Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab)

Shinobu Umemura, Goi Sakamoto, Hironobu Sasano, Hitoshi Tsuda, Futoshi Akiyama, Masafumi Kurosumi, Yutaka Tokuda, Toru Watanabe, Masakazu Toi, Tadashi Hasegawa, R. Yoshiyuki Osamura

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

For the treatment of patients with metastatic breast cancer by humanized anti-human epidermal growth factor receptor type 2 (HER2) antibody (trastuzumab), it is important to evaluate HER2 status adequately. "A guideline for HER2 testing" and "HER2 atlas" produced by the "Pathological committee for optimal use of trastuzumab" are introduced in this report. Appropriate evaluations of biological markers are essential for targeting therapy.

Original languageEnglish
Pages (from-to)316-320
Number of pages5
JournalBreast Cancer
Volume8
Issue number4
DOIs
Publication statusPublished - 2001 Oct

Keywords

  • Breast cancer
  • Fish
  • Guideline
  • HER2
  • Immunohistochemistry
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab)'. Together they form a unique fingerprint.

Cite this